ArticleScience translational medicine2015

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Laura R Saunders et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.